456 related articles for article (PubMed ID: 26916304)
21. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
[TBL] [Abstract][Full Text] [Related]
22. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
[TBL] [Abstract][Full Text] [Related]
23. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
Levi M; Moore KT; Castillejos CF; Kubitza D; Berkowitz SD; Goldhaber SZ; Raghoebar M; Patel MR; Weitz JI; Levy JH
J Thromb Haemost; 2014 Sep; 12(9):1428-36. PubMed ID: 24811969
[TBL] [Abstract][Full Text] [Related]
24. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
Nagakari K; Emmi M; Iba T
Clin Appl Thromb Hemost; 2017 Sep; 23(6):677-684. PubMed ID: 26984934
[TBL] [Abstract][Full Text] [Related]
25. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
Lee FM; Chan AK; Lau KK; Chan HH
Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant Reversal and Anesthetic Considerations.
Meltzer J; Guenzer JR
Anesthesiol Clin; 2017 Jun; 35(2):191-205. PubMed ID: 28526142
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography.
Gantioqui J; Stevic I; Atkinson H; Chan AKC
Blood Coagul Fibrinolysis; 2018 Sep; 29(6):521-527. PubMed ID: 29965810
[TBL] [Abstract][Full Text] [Related]
28. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.
Takeyama M; Sakurai Y; Shima M; Matsumoto T; Nogami K; Tanaka I; Takeda T; Giddings JC; Yoshioka A
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):1-7. PubMed ID: 17179819
[TBL] [Abstract][Full Text] [Related]
29. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
[TBL] [Abstract][Full Text] [Related]
30. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
[TBL] [Abstract][Full Text] [Related]
31. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
Dickneite G; Hoffman M
Thromb Haemost; 2014 Feb; 111(2):189-98. PubMed ID: 24136202
[TBL] [Abstract][Full Text] [Related]
32. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
[TBL] [Abstract][Full Text] [Related]
33. Perioperative use of prothrombin complex concentrates.
Colomina MJ; Díez Lobo A; Garutti I; Gómez-Luque A; Llau JV; Pita E
Minerva Anestesiol; 2012 Mar; 78(3):358-68. PubMed ID: 22357373
[TBL] [Abstract][Full Text] [Related]
34. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal.
Altorjay Á; Szabó É; Boda Z; Kramer L; Ngo LY; Engl W; Firth CL; Ahlstrom ER; Gelmont DM; Pabinger I
Thromb Res; 2015 Mar; 135(3):485-91. PubMed ID: 25613927
[TBL] [Abstract][Full Text] [Related]
35. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
Le Roux P; Pollack CV; Milan M; Schaefer A
J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
[TBL] [Abstract][Full Text] [Related]
36. Compositional differences in commercially available prothrombin complex concentrates.
Sadeghi N; Kahn D; Sayed D; Hoppenstadt D; Jeske W; Harenberg J; Dechristopher P; Fareed J
Clin Appl Thromb Hemost; 2014 Apr; 20(3):256-69. PubMed ID: 24288386
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
38. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
[TBL] [Abstract][Full Text] [Related]
39. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
